When a crisis strikes, organizations often step forward to help. But here’s a question communicators rarely stop to ask: Do disaster relief efforts actually motivate the public—or do they mainly strengthen reputation? That distinction matters more than ever in a communications landscape defined by limited attention, growing skepticism, and rising expectations for corporate responsibility. At […]
Fullintel-UConn study on AI engine citations shows the value of pitching your message to journalists and other credible outlets. If AI is rewriting how audiences discover information, it has also significantly changed how the communications professionals we work with measure impact. Dashboards, sentiment charts, and campaign recaps using traditional media metrics simply can’t sufficiently demonstrate […]
Traditional PR Metrics are Breaking Down – Here’s a New Approach To Help Capitalize on AI Search I’ve spent a lot of time over the past 15+ years counseling clients on how to conduct accurate media analysis to drive successful PR strategies. But the PR landscape is rapidly shifting under all our feet. As that […]
What were the top pharma news stories as of February 2026? Three major pharmaceutical and health technology stories shaped coverage in January 2026: a legal challenge to revised U.S. childhood vaccine guidance, a high-profile AI partnership between Bristol Myers Squibb and Microsoft to improve lung cancer detection, and OpenEvidence’s presentation of an agentic AI–driven vision […]
Every January, the JPM Healthcare Conference sets the tone for the year ahead in pharma and biotech. It’s where strategy meets scrutiny—where investors, analysts, media, and stakeholders look for credible signals about pipelines, leadership, innovation, and long-term growth. This year, I experienced JPM in person for the first time—and it reinforced just how much influence […]
What were the top pharma news stories in January 2026? Three major pharmaceutical news stories dominated December 2025: the Trump administration’s proposed overhaul of childhood vaccine recommendations, voluntary drug pricing agreements under the Most Favored Nation policy, and the FDA’s qualification of AIM-NASH, the first AI tool for MASH clinical trials. January 2026 Pharma News […]
Large language models (LLMs) have transformed the way people search for and consume information. While traditional search engines like Google and Bing remain popular, nearly half of U.S. and European internet users now begin their search with some kind of AI tool. Even traditional search engines now utilize AI-generated summaries, sometimes leading to so-called “zero-click […]
When it comes to evaluating communications performance, one of the most common questions I hear is: “Why don’t we just analyze everything?” It’s an understandable instinct—especially when “big data” has become synonymous with accuracy. But in reality, more data doesn’t always mean better insight. The key to meaningful measurement isn’t volume; it’s representativeness. That’s where […]
This month’s healthcare and pharmaceutical coverage highlights how political pressure, regulatory changes, and new technologies are reshaping access to care and influencing public trust. From government action on drug pricing and funding cuts to HIV programs to debates over AI-driven health advice, the industry faces complex challenges at the intersection of innovation, affordability, and safety. […]
This month’s healthcare and pharmaceutical headlines reflect the growing influence of politics, corporate strategy, and innovation on public health. Limited FDA approval of some COVID vaccines, major acquisitions to expand treatment portfolios, and advances in AI-assisted fertility care show how decisions around access, investment, and technology are shaping the industry. These developments signal a shift […]
